10-QPeriod: Q3 FY2016

HCA Healthcare, Inc. Quarterly Report for Q3 Ended Sep 30, 2016

Filed November 3, 2016For Securities:HCA

Summary

HCA Healthcare, Inc. (HCA) reported solid financial performance for the third quarter and first nine months of 2016. Revenues saw a notable increase, driven by both higher patient volumes and improved revenue per equivalent admission. The company demonstrated strong operational efficiency, with growth across key metrics like admissions and outpatient surgeries. A significant positive development was the resolution of federal income tax issues for tax years 2011 and 2012, which resulted in a substantial tax benefit and boosted net income. The company also continued its strategic financial management, including significant share repurchases and debt refinancing activities aimed at optimizing its capital structure and reducing interest expense. While facing ongoing challenges such as healthcare reform and litigation, HCA's operational execution and financial discipline position it favorably. Investors should note the company's continued investment in capital expenditures and acquisitions as it expands its healthcare network and service offerings.

Financial Highlights

43 data points
Beta

Net Income

$618.00M

EPS (Diluted)

$1.59

Total Assets

$33.13B

Cash & Equivalents

$677.00M

Free Cash Flow

$494.00M

Financial Statements
Beta
Interest Expense$432.00M
Net Income$618.00M
EPS (Basic)$1.63
EPS (Diluted)$1.59
Shares Outstanding (Basic)378.20M
Shares Outstanding (Diluted)389.59M

Key Highlights

  • 1Revenues increased by 4.2% to $10.270 billion for the third quarter of 2016 and by 4.8% to $30.849 billion for the first nine months of 2016, compared to the prior year periods.
  • 2Net income attributable to HCA Holdings, Inc. grew significantly to $618 million ($1.59 per diluted share) for Q3 2016 and $1.970 billion ($4.93 per diluted share) for the first nine months of 2016.
  • 3A substantial tax benefit of $51 million was recognized in Q3 2016 due to the resolution of federal income tax issues for 2011-2012.
  • 4Operating cash flow increased by $105 million to $1.206 billion for Q3 2016 and by $778 million to $3.954 billion for the first nine months of 2016.
  • 5The company repurchased approximately 29.1 million shares of common stock for $2.213 billion during the first nine months of 2016.
  • 6Capital expenditures for the first nine months of 2016 were $1.884 billion, with further investments planned, indicating continued expansion and development.
  • 7The provision for doubtful accounts decreased by $318 million in Q3 2016, indicating improved collectability or changes in patient mix/reimbursement.

Frequently Asked Questions

The significant increase in net income was driven by multiple factors including revenue growth, operational improvements, and importantly, a substantial tax benefit of $51 million resulting from the resolution of federal income tax issues for the 2011 and 2012 tax years. Additionally, adoption of a new accounting standard for share-based payments contributed to the tax benefit.

HCA actively managed its capital structure. The company issued new senior secured notes and term loans while retiring older debt, aiming to optimize its debt profile and potentially reduce interest expense. Furthermore, HCA continued its substantial share repurchase program, buying back approximately 29.1 million shares for $2.213 billion in the first nine months of 2016, which positively impacted earnings per share by reducing the number of outstanding shares.

HCA experienced a 4.2% revenue increase in Q3 2016, driven by a 2.7% increase in revenue per equivalent admission and a 1.5% increase in equivalent admissions. Volume growth was seen in admissions, surgeries, and emergency department visits. The company also noted a decrease in the provision for doubtful accounts, suggesting improved management of patient receivables and potentially a shift in the payer mix.

HCA faces ongoing legal and regulatory scrutiny typical for the healthcare industry. A significant matter is the Health Midwest litigation, where a judgment of $434 million, including compounded interest, was entered, and HCA had accrued $468 million related to this by September 30, 2016, with an appeal ongoing. Additionally, the company is subject to government investigations and potential changes in healthcare regulations, such as those related to the Affordable Care Act and Medicare/Medicaid programs, which could impact future financial performance.